AEZS-150 (Delayed Clearance Parathyroid Hormone Fusion Polypeptides DC-PTH)
Fusion Polypeptides for the Treatment of Primary Hypoparathyroidism
We are working in collaboration with the university of Sheffield to develop AEZS-150 (delayed clearance parathyroid hormone fusion polypeptides DC-PTH) for the treatment of primary hypoparathyroidism.
AEZS-150 (DC-PTH) is a modified growth hormone binding protein (GHBP) linked to PTH1-34 with the goal of providing PTH1-34 with a delayed clearance of one or two weeks. PTH is a key regulating hormone and may help patients with primary hypoparathyroidism maintain normal serum calcium and phosphate levels during chronic use.
PTH is a key regulating hormone essential for calcium homeostasis and renal phosphate clearance
Potential to be a self-administered pen
Developed at leading research university,
The University of Sheffield
~23-37 in every 100,000
people in the US and Europe
Primary hypoparathyroidism is an orphan indication in the field of endocrinology. It is an uncommon condition in which the body produces abnormally low levels of PTH. PTH is a key regulating hormone essential for calcium homeostasis and renal phosphate clearance for maintaining a balance of those two minerals in the body. Untreated, primary hypoparathyroidism will cause, among other effects, renal dysfunction, muscle cramping, twitching, seizures, and cardiac arrhythmias.